Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This visualization, created in partnership with Inigo Insurance, highlights the top brands dominating the $58 billion weight loss drug marketand the powerhouse companies driving their success
Unlike semaglutide, which only targets GLP-1 receptors, tirzepatide is a dual agonist that targets GLP-1 and glucagon receptors
Diarrhea or Constipation: Changes in bowel habits can occur as the digestive system adapts to the medication
18, 187e190
As GLP-1s help improve mobility and reduce pain tied to conditions like osteoarthritis, they can enable more consumers to re-engage with healthier lifestyles, from exercise to more intentional nutrition
US$ 26.85
US$ 21.32
US$ 26.48
US$ 25.09
